APA (7th ed.) Citation

Chae, H., Sim, S. H., Kwon, Y., Lee, E., Han, J. H., Jung, S., . . . Lee, K. S. (2024). Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI). Cancers, 16(18), 3122. https://doi.org/10.3390/cancers16183122

Chicago Style (17th ed.) Citation

Chae, Heejung, et al. "Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI)." Cancers 16, no. 18 (2024): 3122. https://doi.org/10.3390/cancers16183122.

MLA (9th ed.) Citation

Chae, Heejung, et al. "Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI)." Cancers, vol. 16, no. 18, 2024, p. 3122, https://doi.org/10.3390/cancers16183122.